Determinants of measles seroprevalence among pregnant women in Paris, France  by Bodilis, H. et al.
Determinants of measles seroprevalence
among pregnant women in Paris,
France
H. Bodilis1,2, F. Gofﬁnet3,4,5,6, A. Krivine7, T. Andrieu4,
O. Anselem5,6, V. Tsatsaris3,5,6, F. Rozenberg3,6,7 and
O. Launay1,2,3,4,6
1) Inserm, CIC BT 505, 2) Centre d’Investigation Clinique en Vaccinologie,
Assistance Publique-Ho^pitaux de Paris (AP-HP), Ho^pital Cochin,
3) Universite Paris Descartes, Sorbonne Paris Cite, 4) Inserm U953,
5) AP-HP, Ho^pital Cochin, Maternite Port Royal, 6) DHU Risques et
Grossesse, and 7) Department of Virologie, AP-HP, Ho^pital Cochin, Paris,
France
Abstract
Non-immune pregnant women are at risk of severe measles. As
the measles vaccination is contraindicated during pregnancy,
women should be vaccinated before conception or during the
postpartum period. Nevertheless, measles serology is not recom-
mended during pregnancy in France, and there are no data
available concerning measles susceptibility and its associated risk
factors among pregnant women. The socio-demographic deter-
minants of measles seronegativity have been identiﬁed in a
prospective cohort of 826 pregnant women in Paris, France.
Measles seronegativity was 10.41% (95% CI 8.32–12.50). Women
from higher socio-economic groups, born in France after 1980,
were more frequently seronegative.
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Background
Vaccination against measles has been standard practice in
France since 1983: one initial dose at 12 months, with a
second dose (since 1996) recommended initially at 6 years and
now given at18 months. A ‘catch-up’ dose is recommended for
adults born after 1980, who received only one dose during
childhood [1]. There has been an ongoing measles outbreak in
France since 2008, with a high number of cases among infants
under 1 year of age and young adults, including pregnant
women [2]. When measles occurs during pregnancy, maternal
and foetal morbidity is increased [3–5]. In addition, infants
born to seronegative women are not protected until they have
been vaccinated [6–8]. Identiﬁcation of women at risk of
developing measles could help to develop appropriate action
for this population.
Method
The COFLUPREG (COhort on FLU during PREGnancy) study
was a prospective cohort study carried out on pregnant
women in three tertiary maternity centres in Paris (France),
during the 2009 A/H1N1 inﬂuenza pandemic. Nine hundred
and nineteen pregnant women, between 6 and 35 weeks of
gestation, were randomly selected in order to obtain a
representative sample of pregnant women. They were
included from 12 October 2009 to 3 February 2010, in order
to assess the incidence rate of serious forms of A/H1N1
inﬂuenza. Women aged ≥18 years and able to understand
French were eligible to participate [9]. The exclusion criteria
were vaccination for the 2009 A/H1N1 pandemic or a
virologically conﬁrmed 2009 A/H1N1 infection during the
previous 6 months. Socio-demographic and obstetrical char-
acteristics were collected at the time of inclusion. Socio-pro-
fessional categories established by the French INSEE were
ranked in three major groups: upper (managers, engineers and
scientists), middle (teachers, craftsmen, intermediate adminis-
trative and health professionals) and lower (employees,
technicians, the unemployed and manual workers). Because
epidemiological data [1] show that people born before 1980
are naturally protected, two age categories were created: born
either ‘before’ or ‘after’ 1980.
Blood samples were available from 826 women. Measles IgG
antibody levels were measured using the ‘Captia Measles IgG’
technique (Trinity Biotech, Jamestown, NY, USA); < 60 IU/mL
was considered to be negative.
To compare percentages, the v2 or Fisher exact tests were
used whenever n < 5. In order to compare mean values, the
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Student or Mann–Whitney U-test was used whenever n < 30,
and the Kruskall-Wallis test was used when more than two
groups were compared. All possible correlations between the
determinants and measles seronegativity were analysed using
univariate analysis. The determinants having a p-value < 0.25
with the univariate analysis were included in the ﬁnal logistic
regression. Statistical analyses were performed using the
STATA software for Windows (version 11.0; College Station,
Texas, USA).
Results
The characteristics of the population are described in Table 1.
The median age was 33.1 years (minimum, 18.8; maximum,
49.1), 78.4% of the women were born before 1980 and 46.97%
were primiparous. The measles seronegativity rate was 10.41%
(95% CI 8.32–12.50) for the full sample population, 8.64%
(95% CI 6.47–10.81) for women born before 1980, and
16.85% (95% CI 11.30–22.41) for women born after 1980.
Among women with measles antibodies, the mean titre was
502.3 IU/mL (range 60–2510): 399.9 IU/mL for women born
after 1980 and 527.9 IU/mL for those born before
(p = 0.0001). The univariate analysis showed that age, geo-
graphical origin and number of children aged <18 years living at
home were signiﬁcantly associated with measles seronegativity
(Table 1). In the multivariate logistic regression, the determi-
nants associated with measles seronegativity were: age (18–
29 years, adjusted odds ratio (aOR) 2.5, 95% CI 1.5–4.1;
compared with the 30–50 years age group), geographical
origin (sub-Saharan African origin, aOR 0.5, 95% CI 0.2–1.4;
North African origin, aOR 0.9, 95% CI 0.4–2.1; Asian origin,
aOR 2.6, 95% CI 1.2–5.4; compared with French and European
origin), and socio-economic category (middle or lower
socio-economic category, aOR 0.5, 95% CI 0.3–0.9; compared
with the upper socio-economic category) (Table 2).
TABLE 1. Characteristics of the studied population and determinants associated with measles serosusceptibility: univariate
analysis
Total No. (%)
Measles IgG
negative No. (%)
Measles IgG
positive No. (%) p-valuea,b,c
Total 826 (100) 86 (10.41) 740 (89.59)
Maternity Centre (France)
Saint Vincent de Paul 234 (28.33) 23 (9.83) 211 (90.17) 0.012a
Port Royal 397 (48.06) 32 (8.06) 365 (91.94)
Necker 195 (23.61) 31 (15.90) 164 (84.10)
Age (mean, years) 33.06 31.12 33.29 <0.0001c
19–24 23 (2.78) 4 (17.39) 19 (82.61) 0.004a
25–29 155 (18.77) 26 (16.77) 129 (83.23)
30–34 327 (39.59) 37 (11.31) 290 (88.69)
35–39 210 (25.42) 14 (6.67) 196 (93.33)
40–50 111 (13.44) 5 (4.50) 106 (95.50)
Year of birth before 1980 648 (78.45) 56 (8.64) 592 (91.36) 0.001a
Born after 1980 178 (21.55) 30 (16.85) 148 (83.15)
Geographical origin (N = 823)
French/European 603 (73.27) 63 (10.45) 540 (89.55) 0.024a
Sub-Saharan Africa/West Indies 85 (10.33) 5 (5.88) 80 (94.12)
North Africa 85 (10.33) 7 (8.24) 78 (91.76)
Asian and Other 50 (6.08) 11 (22.00) 39 (78.00)
Socio-economic category (N = 825)
Upper 312 (37.82) 41 (13.14) 271 (86.86) 0.137a
Middle 276 (33.45) 24 (8.70) 252 (91.30)
Lower 237 (28.73) 21 (8.86) 216 (91.14)
Healthcare worker (N = 544)
Yes 120 (22.06) 9 (7.50) 111 (92.50) 0.204a
No 424 (77.94) 49 (11.56) 375 (88.44)
Professionals in contact with the
public (N = 446)
Yes 380 (85.20) 39 (10.26) 341 (89.74) 0.334b
No 66 (14.80) 4 (6.06) 62 (93.94)
Working with children (N = 445)
Yes 82 (18.43) 9 (10.98) 73 (89.02) 0.89a
No 363 (81.57) 33 (9.09) 330 (90.91)
Status (N = 825)
In couple 570 (93.33) 84 (10.91) 686 (89.09) 0.108b
Single 55 (6.67) 2 (3.64) 53 (96.36)
Gestity (mean) 2.34 2.10 2.37 0.055d
Number of children<18 years living
at home (mean)
0.73 0.58 0.75 0.045d
Parity
0.1 686 (83.05) 76 (11.08) 610 (88.92) 0.165a
>1 140 (16.95) 10 (7.14) 130 (92.86)
av2, bFisher exact test, cStudent, dWelch.
Bold values indicate statistical signiﬁcance (p <0.05).
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Discussion
This study, conducted during a signiﬁcant measles epidemic in
France, shows that 10% of pregnant women were susceptible
to measles, and this percentage increased to 17% for women
born after 1980.
Age was the most important factor associated with
seronegativity. This may be the consequence of a decrease in
the circulation of the virus, or a secondary effect resulting
from the generalized measles vaccination programme and
insufﬁcient vaccination coverage, especially in the case of the
second dose. In the pre-vaccine era, natural measles infections
led to life-long protective immunity [10–12]. In the present
study, women born after 1980 had signiﬁcantly lower antibody
levels than older women, reﬂecting lower antibody titres
produced by vaccination than by natural infection [5–7, 11, 12,
18]. The women’s socio-economic category was also associated
with seronegativity. A high level of education was generally
associated with a lower exposure to natural infection.
These results are in agreement with studies carried out in
the general population and women of child-bearing age in
other countries, revealing seronegativity rates varying between
5% and 20% [13–19]. Factors correlated with seronegativity
were: young women (aged between 15 and 29 years), a high
level of education, less than four pregnancies, and standard of
living above the poverty line.
The main limitation of our study is the lack of data related
to measles vaccination and disease history. Although pregnant
women are not representative of the general population, the
high number of patients included in the study, together with its
prospective design, made it possible to determine and
generalize the main risk factors associated with a lack of
protection against measles.
The rate of measles susceptibility, together with its risk of
complications for the mother and the foetus, is particularly
high among pregnant women born after 1980, who are of
French origin and belong to the upper socio-economic
category. Measles serology could be carried out in these
women during pregnancy: those found to be seronegative
could be advised to receive measles immunoglobulin in
situations where they could come into contact with a
documented case of measles; they could then be vaccinated
during the postpartum period.
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